Moderna/$MRNA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Ticker
$MRNA
Sector
Primary listing
Employees
5,800
Headquarters
Website
Moderna Metrics
BasicAdvanced
$11B
-
-$7.53
1.93
-
Price and volume
Market cap
$11B
Beta
1.93
52-week high
$57.90
52-week low
$23.15
Average daily volume
12M
Financial strength
Current ratio
3.926
Quick ratio
3.555
Long term debt to equity
7.426
Total debt to equity
7.884
Interest coverage (TTM)
-233.79%
Profitability
EBITDA (TTM)
-3,065
Gross margin (TTM)
-71.44%
Net profit margin (TTM)
-94.31%
Operating margin (TTM)
-106.34%
Effective tax rate (TTM)
1.43%
Revenue per employee (TTM)
$530,000
Management effectiveness
Return on assets (TTM)
-14.78%
Return on equity (TTM)
-27.50%
Valuation
Price to revenue (TTM)
3.501
Price to book
1.16
Price to tangible book (TTM)
1.17
Price to free cash flow (TTM)
-3.079
Free cash flow yield (TTM)
-32.48%
Free cash flow per share (TTM)
-9.067
Growth
Revenue change (TTM)
-39.05%
Earnings per share change (TTM)
-50.99%
3-year revenue growth (CAGR)
-48.85%
3-year earnings per share growth (CAGR)
-38.82%
What the Analysts think about Moderna
Analyst ratings (Buy, Hold, Sell) for Moderna stock.
Bulls say / Bears say
The FDA expanded approval of Moderna’s RSV vaccine, mRESVIA, to adults aged 18–59 at higher risk of severe illness, widening its market beyond those 60 and older and increasing long-term revenue potential (Reuters)
Moderna’s Spikevax COVID-19 vaccine received full FDA approval for children aged six months through 11 years with high-risk conditions, opening a new pediatric revenue stream for the 2025–2026 respiratory season (Reuters)
By late August, the FDA approved Moderna’s next-generation COVID-19 vaccine, mNEXSPIKE, for people 65+ and high-risk adults 12–64, strengthening Moderna’s leadership in the high-risk COVID-19 booster market (Reuters)
The U.S. Department of Health and Human Services will end BARDA’s mRNA vaccine development program, canceling Moderna’s late-stage bird flu vaccine contract and taking away almost $500 million in expected funding, weakening the company’s pandemic influenza pipeline (Reuters)
Moderna withdrew its FDA application for the combined COVID-19 and flu vaccine after feedback from the agency, pushing approval to 2026 and raising doubts about the company’s ability to quickly bring next-generation respiratory vaccines to market (Reuters)
The company announced a 10% workforce reduction to lower expenses by $1.5 billion by 2027 as COVID-19 and RSV vaccine sales fall, signaling growing revenue challenges and a share price drop of over 20% this year (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
Moderna Financial Performance
Revenues and expenses
Moderna Earnings Performance
Company profitability
Moderna News
AllArticlesVideos
Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK
Accesswire2 weeks ago
Moderna says updated next-generation COVID shot shows strong immune response in patients
Reuters2 weeks ago
Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans
Accesswire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Moderna stock?
Moderna (MRNA) has a market cap of $11B as of October 09, 2025.
What is the P/E ratio for Moderna stock?
The price to earnings (P/E) ratio for Moderna (MRNA) stock is 0 as of October 09, 2025.
Does Moderna stock pay dividends?
No, Moderna (MRNA) stock does not pay dividends to its shareholders as of October 09, 2025.
When is the next Moderna dividend payment date?
Moderna (MRNA) stock does not pay dividends to its shareholders.
What is the beta indicator for Moderna?
Moderna (MRNA) has a beta rating of 1.93. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.